In IME tumor, tumor cells with high expression of CD19 are even encapsulated inside the tumor, making it difficult for CAR-T cells to play a targeting role, which is likely to be one of the reasons for the greatly reduced therapeutic effect (Fig. 7B). This evidence concerns the gene CD19 and neoplasm.